Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 31997R1838

    Commission Regulation (EC) No 1838/97 of 24 September 1997 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance)

    OJ L 263, 25.9.1997, p. 14–18 (ES, DA, DE, EL, EN, FR, IT, NL, PT, FI, SV)

    This document has been published in a special edition(s) (CS, ET, LV, LT, HU, MT, PL, SK, SL, BG, RO)

    Legal status of the document No longer in force, Date of end of validity: 05/07/2009; Implicitly repealed by 32009R0470

    ELI: http://data.europa.eu/eli/reg/1997/1838/oj

    25.9.1997   

    EN

    Official Journal of the European Communities

    L 263/14


    COMMISSION REGULATION (EC) No 1838/97

    of 24 September 1997

    amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin

    (Text with EEA relevance)

    THE COMMISSION OF THE EUROPEAN COMMUNITIES,

    Having regard to the Treaty establishing the European Community,

    Having regard to Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (1), as last amended by Commission Regulation (EC) No 749/97 (2), and in particular Articles 6, 7 and 8 thereof,

    Whereas, in accordance with Regulation (EEC) No 2377/90, maximum residue limits must be established progressively for all pharmacologically active substances which are used within the Community in veterinary medicinal products intended for administration to food-producing animals;

    Whereas maximum residue limits should be established only after the examination within the Committee for Veterinary Medicinal Products of all the relevant information concerning the safety of residues of the substance concerned for the consumer of foodstuffs of animal origin and the impact of residues on the industrial processing of foodstuffs;

    Whereas, in establishing maximum residue limits for residues of veterinary medicinal products in foodstuffs of animal origin, it is necessary to specify the animal species in which residues may be present, the levels which may be present in each of the relevant meat tissues obtained from the treated animal (target tissue) and the nature of the residue which is relevant for the monitoring of residues (marker residue);

    Whereas, for the control of residues, as provided for in appropriate Community legislation, maximum residue limits should usually be established for the target tissues of liver or kidney, whereas, however, the liver and kidney are frequently removed from carcases moving in international trade, and maximum residue limits should therefore also always be established for muscle or fat tissues;

    Whereas, in the case of veterinary medicinal products intended for use in laying birds, lactating animals or honey bees, maximum residue limits must also be established for eggs, milk or honey;

    Whereas, baquiloprim, tylosin and tolfenamic acid should be inserted into Annex I to Regulation (EEC) No 2377/90;

    Whereas bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, bismuth subsalicylate, cloprostenol, r-cloprostenol and luprostiol should be inserted into Annex II to Regulation (EEC) No 2377/90;

    Whereas, in order to allow for the completion of scientific studies, apramycin should be inserted into Annex III to Regulation (EEC) No 2377/90;

    Whereas a period of 60 days should be allowed before the entry into force of this Regulation in order to allow Member States to make any adjustment which may be necessary to the authorizations to place the veterinary medicinal products concerned on the market which have been granted in accordance with Council Directive 81/851/EEC (3), as last amended by Directive 93/40/EEC (4), to take account of the provisions of this Regulation;

    Whereas the measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,

    HAS ADOPTED THIS REGULATION:

    Article 1

    Annexes I, II and III to Regulation (EEC) No 2377/90 are hereby amended as set out in the Annex hereto.

    Article 2

    This Regulation shall enter into force on the 60th day following its publication in the Official Journal of the European Communities.

    This Regulation shall be binding in its entirety and directly applicable in all Member States.

    Done at Brussels, 24 September 1997.

    For the Commission

    Martin BANGEMANN

    Member of the Commission


    (1)  OJ L 224, 18. 8. 1990, p. 1.

    (2)  OJ L 110, 26. 4. 1997, p. 24.

    (3)  OJ L 317, 6. 11. 1981, p. 1.

    (4)  OJ L 214, 24. 8. 1993, p. 31.


    ANNEX

    The Annexes to Regulation (EEC) No 2377/90 are hereby amended as follows:

    A.

    Annex I is amended as follows:

    1.

    Anti-infectious agents

    1.1.

    Chemotherapeutics

    1.1.2.

    Diamino pyrimidine derivates

    Pharmacologically active substance

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    ‘1.1.2.1.

    Baquiloprim

    Baquiloprim

    Bovine

    10 μg/kg

    Fat

     

    300 μg/kg

    Liver

    150 μg/kg

    Kidney

    30 μg/kg

    Milk

    Porcine

    40 μg/kg

    Skin + fat

    50 μg/kg

    Liver, kidney’

    1.2.

    Antibiotics

    1.2.4.

    Macrolides

    Pharmacologically active substance

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    ‘1.2.4.3.

    Tylosin

    Tylosin A

    Bovine

    100 μg/kg

    Muscle, fat, liver, kidney

     

    50 μg/kg

    Milk

    Porcine

    100 μg/kg

    Muscle, skin + fat, liver, kidney

    Poultry

    100 μg/kg

    Muscle, skin + fat, liver, kidney

    Not for use in hens producing eggs for human consumption’

    4.

    Anti-inflammatory agents

    4.1.

    Nonsteroidal anti-inflammatory agents

    4.1.2.

    Fenamate group derivatives

    Pharmacologically active substance

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    ‘4.1.2.1.

    Tolfenamic acid

    Tolfenamic acid

    Bovine

    50 μg/kg

    Muscle

     

    400 μg/kg

    Liver

    100 μg/kg

    Kidney

    50 μg/kg

    Milk

    Porcine

    50 μg/kg

    Muscle

    400 μg/kg

    Liver

    100 μg/kg

    Kidney’

    B.

    Annex II is amended as follows:

    1.

    Inorganic compounds

    Pharmacologically active substance(s)

    Animal species

    Other provisions

    ‘1.30.

    Bismuth subcarbonate

    All food-producing species

    For oral use only

    1.31.

    Bismuth subgallate

    All food-producing species

    For oral use only

    1.32.

    Bismuth subnitrate

    All food-producing species

    For oral use only

    1.33.

    Bismuth subsalicylate

    All food-producing species

    For oral use only’

    2.

    Organic compounds

    Pharmacologically active substance(s)

    Animal species

    Other provisions

    ‘2.79.

    Cloprostenol

    Bovine, porcine, equidae

     

    2.80.

    R-Cloprostenol

    Bovine, porcine, equidae

     

    2.81.

    Luprostiol

    All mammalian species’

     

    C.

    Annex III is amended as follows:

    1.

    Anti-infectious agents

    1.2.

    Antibiotics

    1.2.5.

    Aminoglycosides

    Pharmacologically active substance

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    ‘1.2.5.7.

    Apramycin

    Apramycin

    Bovine

    1 000 μg/kg

    Muscle, fat

    For use in non-lactating cattle only Provisional MRLs expire on 1. 7. 1999

    10 000 μg/kg

    Liver

    20 000 μg/kg

    Kidney

    Porcine

    1 000 μg/kg

    Muscle, skin + fat, liver

    Provisional MRLs expire on 1. 7. 1999’

    5 000 μg/kg

    Kidney


    Top